Moderna Adjusts 2025 Financial Forecast Due to UK Vaccine Shipment Delay
Moderna announced a reduction in the upper limit of its revenue projection for 2025 owing to a postponement in vaccine deliveries to the United Kingdom. Concurrently, the company exceeded Wall Street's financial predictions for the second quarter while continuing to implement cost-reducing strategies.
On Friday, shares of Moderna saw a decrease of over 5% during premarket trading.
The biotechnology firm now anticipates annual earnings to range between $1.5 billion and $2.2 billion, reducing $300 million from the previously anticipated peak. This financial update follows a previous announcement about further steps to minimize costs as Moderna addresses declining Covid vaccine sales and aims to launch additional products.
Vaccine Shipment Rescheduling
In a recent discussion, CFO Jamey Mock clarified that rather than dispatching the spring batch of Covid boosters to the UK before year's end, shipments would now occur in the first quarter of 2026. Despite this logistical shift, Mock assured that the contract's total value remains unaffected.
"This adjustment simply shifts our delivery timeline from our fiscal year's conclusion to the UK's fiscal year's culmination next year to accommodate the spring booster supply," Mock explained.
Financial Performance Exceeds Expectations
Also on Friday, Moderna announced a smaller-than-anticipated loss for the second quarter and revenue figures that surpassed forecasts.
For the second quarter, Moderna's sales amounted to $142 million, marking a 41% decline from the previous year's equivalent timeframe due to shrinking Covid vaccine revenue. Nonetheless, its Covid-19 vaccine accounted for $114 million of this income.
These figures were notably higher than analysts' projections of $89 million, as compiled by StreetAccount.
Conversely, sales of Moderna's respiratory syncytial virus vaccine were minimal, contrary to the $5.9 million anticipated by analysts, as indicated by StreetAccount.
Second Quarter Losses and Cost Reductions
The company recorded a net loss of $825 million, equivalent to $2.13 per share, in the second quarter, which was an improvement over the $1.3 billion or $3.33 per share loss during the same quarter last year.
Mock attributed beating quarterly forecasts to Moderna's successful cost reduction efforts, noting that operational expenses for the second quarter fell by 27%, reducing to $1.1 billion from the prior year's $1.6 billion during the same interval.
"What stands out in the first half of 2025 from a financial standpoint is the emphasis on cost management," Mock remarked.



Leave a Reply